ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors
Potential First-In-Class Agent
Executive Summary
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
You may also be interested in...
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
AZ Bets Big On ADCs As It Inks Second, $6bn Deal With Daiichi
Following their original March 2019 tie-up for an oncology antibody-drug conjugate, Daiichi Sankyo and AstraZeneca have entered into a new global deal worth up to $6bn for a second novel asset from the Japanese firm, with potential in breast, lung and other cancers.
AZ Closer To Second Enhertu OK After Gastric Cancer Success
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.